Managing pleasures and harms: An ethnographic study of drug consumption in public spaces, homes and drug consumption rooms

https://doi.org/10.18294/sc.2020.2481

Published 21 July 2020 Open Access


Rafael Clua-García PhD in Social and Cultural Anthropology. Associate Professor, Facultad de Ciencias de la Salud de Manresa, Universitat de Vic - Universitat Central de Catalunya, Manresa, Spain. image/svg+xml



Abstract views
1437
Metrics Loading ...

Crossref
Scopus
Google Scholar
Europe PMC

Keywords:

Drug Users, Harm Reduction, Needle-Exchange Programs, Qualitative Research, Heroin Dependence, Cocaine, Spain

Abstract


Drug consumption rooms (DCR) aim to facilitate consumption in hygienic and safe conditions. However, users also consume drugs in public spaces and homes generating incremental risk for health. To strengthen our understanding of consumption practices, we conducted an ethnographic study in different consumption locations in Barcelona, including DCRs, public spaces, and homes. Focusing on consumption practices and narratives, we conducted participant observation and interviewed 16 DCR users. Our findings show that different consumption spaces allow users to experiment different types of pleasures. In addition, consumption in each type of location is associated with various types of harms, which are managed by users by self-regulating their practices. These aspects, therefore, must be taken into account to design harm reduction action aligned with users’ practices.


References


1. Bosque-Prous M, Brugal MT. Intervenciones de reducción de daños en usuarios de drogas: situación actual y recomendaciones. Gaceta Sanitaria. 2016;30(Supl 1):104-110.

2. Folch C, Lorente N, Majó X, Parés-Badell O, Roca X, Brugal T, Roux P, Carrieri P, Colom J, Casabona J, REDAN study group. Drug consumption rooms in Catalonia: A comprehensive evaluation of social, health and harm reduction benefits. International Journal of Drug Policy. 2018;62:24-29.

3. Clua R, Tenza G, Mingueza J. Guia de bones pràctiques en els programes d’intercanvi de xeringues. Barcelona: Agencia de Salut Publica de Catalunya; 2015.

4. Dennis BB, Naji L, Bawor M, Bonner A, Varenbut M, Daiter J, Plater C, Pare G, Marsh DC, Worster A, Desai D, Samaan Z, Thabane L. The effectiveness of opioid substitution treatments for patients with opioid dependence: a systematic review and multiple treatment comparison protocol. Systematic Reviews. 2014;3:105.

5. Potier C, Laprévote V, Dubois-Arber F, Cottencin O, Rolland B. Supervised injection services: what has been demonstrated?: A systematic literature review. Drug Alcohol Depend. 2014;145:48-68.

6. Hedrich D, Kerr T, Dubois-Arbe F. Drug consumption facilities in Europe and beyond. En: Rhodes T, Hedrich D. (eds.) Harm reduction: Evidence, impacts and challenges. Luxembourg: European Monitoring Centre for Drugs and Drug Addiction; 2010. p. 305-331.

7. Noël L, Gagnon F, Bédard A, Dubé È. Avis sur la pertinence des services d’injection supervisée: analyse critique de la littérature. Québec: Institut national de santé publique du Québec; 2009.

8. Clua R. Salas de consumo higiénico en España (2000-2013). Salud Colectiva. 2015;11(2):261-282.

9. Bertrand B. Salles de shoot? Un regard engagé en faveur de l’expérimentation de structures d’accueil avec possibilité de consommer à moindre risque des drogues. Paris: Books on Demand; 2010.

10. Espelt A, Villalbí JR, Bosque-Prous M, Parés-Badell O, Mari-Dell’Olmo M, Brugal MT. The impact of harm reduction programs and police interventions on the number of syringes collected from public spaces: a time series analysis in Barcelona, 2004-2014. International Journal of Drug Policy. 2017;50:11-18.

11. Vecino C, Villalbí JR, Guitart A, Espelt A, Bartroli M, Castellano Y, Brugal MT. Apertura de espacios de consumo higiénico y actuaciones policiales en zonas con fuerte tráfico de drogas: Evaluación mediante el recuento de las jeringas abandonadas en el espacio público. Adicciones. 2013;25(4):333-338.

12. Anoro M, Ilundain E, Santisteban O. Barcelona’s Safer Injection Facility-EVA: A Harm Reduction Program Lacking Official Support. Journal of Drug Issues. 2003;33(3):689-711.

13. Agència de Salut Pública de Catalunya. Informe anual 2017. Sistema d’informació sobre drogodependències a Catalunya. Barcelona: Generalitat de Catalunya; 2018.

14. Clua R. Estilos de vida de los usuarios de las salas de consumo higiénico de Barcelona. Health and Addictions, Salud y Drogas. 2018;18(2):79-89.

15. Folch C, Casabona J, Brugal MT, Majó X, Meroño M, Espelt A, González V. Perfil de los usuarios de drogas por vía parenteral que mantienen conductas de riesgo relacionadas con la inyección en Cataluña. Gaceta Sanitaria. 2012;26(1):37-44.

16. Haro JA. Cuidados profanos: una dimensión ambigua en la atención de la salud. En: Perdiguero E, Comelles J. (coord.). Medicina y cultura: estudios entre la antropología y la medicina. Barcelona: Bellaterra; 2000. p. 101-161.

17. Rhodes T. The ‘risk’ environment: A framework for understanding and reducing drug related harm. International Journal of Drug Policy. 2002;13:85-94.

18. Rhodes T. Risk environments and drug harms: a social science for harm reduction approach. International Journal of Drug Policy. 2009;20(3):193-292.

19. Llort Suárez A. «Dime dónde consumes y te diré…»: Antropología sobre el uso y abuso de cocaína. Perifèria, Revista de Recerca i Formació en Antropologia. 2018;23(1):56-83.

20. Sepúlveda M, Romaní O. Conceptualización y políticas de la gestión del riesgo. En: Martínez Oró DP, Pallarés J, (eds.). De riesgos y placeres: manual para entender las drogas. Lleida: Milenio; 2013. p. 89-102.

21. Duff C. Towards a theory of drug use contexts: Space, embodiment and practice. Addiction Research and Theory. 2007;15(5):503-519.

22. Duff C. The pleasure in context. International Journal of Drug Policy. 2008;19(5):384-392.

23. Martínez Oró DP, Pallarés J. Riesgos, daños y placeres. En: Martínez Oró DP, Pallarés J, (eds.). De riesgos y placeres: manual para entender las drogas. Lleida: Milenio; 2013. p. 23-36.

24. Dilkes-Frayne E. Tracing the “event” of drug use: “Context” and the coproduction of a night out on MDMA. Contemporary Drug Problems. 2014;41(3):445-479.

25. Martínez Oró DP, Romaní O. Els danys de les polítiques prohibicionistes en l’àmbit de les drogues. Quaderns-E. 2016;21(1):33-49.

26. Clua R. ¡Apúntame a la sala!: Epidemiología sociocultural del consumo de drogas y evaluación de las políticas de reducción de daños en las salas de consumo higiénico de Barcelona. [Tesis Doctoral]. Departament d´Antropologia Social i Cultural de la UAB; 2016.

27. Clua R. Atención de enfermería del síndrome posconsumo de cocaína en usuarios de las salas de consumo higiénico de Barcelona. IV Congreso Virtual Internacional de Enfermería en Salud Mental [Internet]. 2018;4 [citado 10 may 2019]. Disponible en: http://psiqu.com/1-8944

28. Bourgois P, Schonberg J. Righteous Dopefiend. Berkeley: University of California Press; 2009.

29. Carlson RG, Singer M, Stephens RC, Sterk CE. Reflections on 40 years of ethnographic drug abuse research: Implications for the future. Journal of Drug Issues. 2009;39(1):57-70.

30. Singer M. Anthropology and addiction: An historical review. Addiction. 2012;107(10):1747-1755.

31. Romaní O. La epidemiología sociocultural en el campo de las drogas: contextos, sujetos y sustancias. En: Haro JA, (coord.). El planteamiento de una epidemiología sociocultural. Un diálogo en torno a su sentido, métodos y alcances. Buenos Aires: Lugar; 2010. p. 89-113.

32. Agència de Salut Pública de Catalunya. Informe anual 2015. Sistema d’informació sobre drogodependències a Catalunya. Barcelona: Generalitat de Catalunya; 2016.

33. Martínez-Salgado C. El muestreo en investigación cualitativa: principios básicos y algunas controversias. Ciência & Saúde Coletiva. 2012;17(3):613-619.

34. Shaghaghi A, Bhopal RS, Sheikh A. Approaches to recruiting “Hard-To-Reach” populations into research: A review of the literature. Health Promotion Perspectives. 2011;1(2):86-94.

35. Hammersley M, Atkinson P. Ethnography: principles in practice. Third edition. London: Routledge; 2007.

36. Emerson RM, Fretz R, Shaw LL. Writing ethnographic fieldnotes. Chicago: University of Chicago Press; 2011.

37. DiCicco-Bloom B, Crabtree BF. The qualitative research interview. Medical Education. 2006;40(4):314-321.

38. Jamshed S. Qualitative research method-interviewing and observation. Journal of Basic and Clinical Pharmacy. 2014;5(4):87-88.

39. Bengtsson M. How to plan and perform a qualitative study using content analysis. NursingPlus Open. 2016;2:8-14.

40. Carter N, Bryant-Lukosius D, DiCenso A, Blythe J, Neville AJ. The use of triangulation in qualitative research. Oncology Nursing Forum. 2014;41(5):545-547.

41. Duncan T, Duff C, Sebar B, Lee J. ‘Enjoying the kick’: Locating pleasure within the drug consumption room. International Journal of Drug Policy. 2017;49:92-101.

42. Martínez Oró DP. Sin pasarse de la raya. La normalización de los consumos de drogas. Barcelona: Bellaterra; 2015.

43. Sarasa-Renedo A, Espelt A, Folch C, Vecino C, Majó X, Castellano Y, Casabona J, Brugal MT, Redan Study Group. Overdose prevention in injecting opioid users: the role of substance abuse treatment and training programs. Gaceta Sanitaria. 2014;28(2):146-54.

44. Domoslawski A. Drug policy in Portugal: The benefits of decriminalizing drug use. Warsaw: Open Society Foundations; 2011.

45. Bardwell G, Strike C, Altenberg J, Barnaby L, Kerr T. Implementation contexts and the impact of policing on access to supervised consumption services in Toronto, Canada: a qualitative comparative analysis. Harm Reduct J. 2019;16(1):30.

46. Shaw A, Lazarus L, Pantalone T, LeBlanc S, Lin D, Stanley D, Chepesiuk C, Patel S, Tyndall M. Risk environments facing potential users of a supervised injection site in Ottawa, Canada. Harm Reduction Journal. 2015;12:49.

47. Moore D. Erasing pleasure from public discourse on illicit drugs: On the creation and reproduction of an absence. International Journal of Drug Policy. 2008;19(5):353-358.

48. Brugal MT, Guitart AM, Espelt A, (eds.). Pla d’Acció sobre Drogues de Barcelona 2013-16. Barcelona: Agència de Salut Pública de Barcelona; 2013.

49. Espelt A, Major X, Parés-Badell O, Carvajal S, Gasulla L, Bosque-Prous M, Brugal, MT. Implementation of Systematic Programs of Overdose Training at Drug Treatment and Prevention Centres in Catalonia, 2008-2013. En: Dichtl A, Stöver H (eds.). Naloxon - Überlebenshilfe im Drogennotfall. Frankfurt: Fachhochschulverlag; 2015. p. 83-95.

50. Holloway K, Hills R, May T. Fatal and non-fatal overdose among opiate users in South Wales: A qualitative study of peer responses. The International Journal on Drug Policy. 2018;56:56-63.

51. Latkin CA, Gicquelais RE, Clyde C, Dayton L, Davey-Rothwell M, German D, Falade-Nwulia S, Saleem H, Fingerhood M, Tobin K. Stigma and drug use settings as correlates of self-reported, non-fatal overdose among people who use drugs in Baltimore, Maryland. International Journal of Drug Policy. 2019;68:86-92.

52. Jozaghi E, Andresen MM. Should North America’s first and only supervised injection facility (InSite) be expanded in British Columbia, Canada? Harm Reduction Journal. 2013;10:1.

53. Small W, Moore D, Shoveller J, Wood E, Kerr T. Perceptions of risk and safety within injection settings: Injection drug users’ reasons for attending a supervised injecting facility in Vancouver, Canada. Health, Risk & Society. 2012;14(4):307-24.

54. Delàs J, Priore AG, Pigem A, Aguas M. Síndrome posconsumo de cocaína inyectada a partir de las observaciones en una sala de consumo supervisada. Medicina Clínica. 2008;130(1):35.

55. Roncero C, Martínez-Luna N, Daigre C, Grau-López L, Gonzalvo B, Pérez-Pazos J, Casas M. Psychotic symptoms of cocaine self-injectors in a harm reduction program. Substance Abuse. 2013;34(2):118-121.

56. Delàs J, Adán E, Díaz O, Aguas M, Pons M, Fuertes R. Smoked cocaine in socially-depressed areas. Harm Reduction Journal. 2010;7:27.